Sildenafil Citrate Tablet, Film Coated
Product Images NDC 71335-3049

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 71335-3049). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image Description (Logo1)

Image Description (Logo1)
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
Data provided shows the change in systolic blood pressure (SBP) in mmHg over time postdose for two different treatments: Doxazosin + Placebo and Doxazosin + Sildenafil 25 mg. The values at time points 5, 6, and 7 hours postdose are mentioned. These results can be used to evaluate the effectiveness and impact of the treatments on SBP.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
This text lists different treatments with Doxazosin combined with either Sildenafil 100 mg or Placebo. It also suggests a time frame "Time After Dosing (hr)" for evaluation. The measurement unit mentioned is mmHg, indicating that the evaluation is likely related to blood pressure.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
This is a description of plasma concentrations (in ng/mL) at different time points post-dose for a treatment involving a commercial tablet. The concentrations are measured at the specified time intervals to evaluate the drug's pharmacokinetics.*
FDA Label Image

Figure-6-1 (Figure 6 1)

Figure-6-1 (Figure 6 1)
This is a data set showing the percentage of patients at different endpoints, along with baseline score. The percentages for the endpoints are: 80%, 70%, 60%, 5%, 8%, 4%, 8%, 3%, 8%, 2%, 3%, 1%, 3%.*
FDA Label Image

Figure-6-2 (Figure 6 2)

Figure-6-2 (Figure 6 2)
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
This is a table showing the percentage of patients reporting improvement with different dosages of sildenafil citrate compared to a placebo. The patients were divided into groups based on the dosage of sildenafil citrate (25mg, 50mg, 100mg) and a placebo group, with the corresponding number of patients in each group provided. The results indicate the percentage of patients reporting improvement for each group.*
FDA Label Image

Label (Lbl713353049)

Label (Lbl713353049)
Each film-coated tablet contains Sildenafil Citrate, USP equivalent to 100 mg of sildenafil. The tablets are to be stored at 20° to 25°C (68° to 77°F) in a tight, light-resistant container and kept out of reach of children. This medication is recommended to be dispensed as per pharmacy regulations. For proper usage, refer to the package insert.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.